With prospects for an AstraZeneca Plc deal falling apart, Pfizer Inc. Chief Executive Officer Ian Read is facing a new question from investors: What now?
Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
Mylan Inc., the biggest U.S. generic-drug maker, was rejected in its bid to buy Meda AB, the Swedish pharmaceuticals maker valued at about $4.5 billion.
"They're just not performing as well, so they kind of need those sales."
- Jeff Jonas on Nov 04, 2014
Bloomberg Surveillance: Levkovich, Moffatt and Jonas
Gabelli’s Jonas Says Pfizer Deal Will Get Done (Audio)
Gabelli’s Jonas Says CVS Can Maintain Current Growth (Audio)
Jonas Discusses Cigna Pharmacy-Benefits Division
Gabelli's Jonas, Edward Jones's Clark on CVS Outlook (Audio)